Loading…
CG Oncology, Inc. is projected to rise to $89.64 by 2027, a +47% move from its current price of $60.80. CGON is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $59.35 | $60.84 | $62.37 | +0.06% |
| May 30 | $58.78 | $60.87 | $63.05 | +0.12% |
| May 31 | $58.35 | $60.91 | $63.59 | +0.18% |
| Jun 1 | $58.00 | $60.95 | $64.05 | +0.24% |
| Jun 2 | $57.69 | $60.99 | $64.46 | +0.31% |
| Jun 3 | $57.42 | $61.02 | $64.85 | +0.37% |
| Jun 4 | $57.18 | $61.06 | $65.20 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $57.18 | $61.06 | $65.20 | +0.43% |
| Week 2 | $55.89 | $61.32 | $67.29 | +0.86% |
| Week 3 | $54.97 | $61.58 | $69.00 | +1.29% |
| Week 4 | $54.24 | $61.85 | $70.52 | +1.72% |
| Week 5 | $53.63 | $62.11 | $71.93 | +2.16% |
| Week 6 | $53.11 | $62.38 | $73.26 | +2.59% |
| Week 7 | $52.66 | $62.64 | $74.52 | +3.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors.
It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc.
in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
CG Oncology, Inc. trades under the symbol CGON, with a current price of $64.25 and a market cap of $5.67B. It is ranked 1258. The price outlook is bullish over the longer horizon, with a year-by-year forecast showing upside starting from 2027.
The 2026 average price is $64.25, progressing to $97.17 in 2027, $112.59 in 2028, and $122.08 in 2029, reaching $146.36 on average in 2030. The forecast continues to rise beyond 2030, with 2040 average $485.13 and 2050 average $921.71. The implied upside is evident in the max values: 2026 max $96.43, 2027 max $128.29, 2028 max $153.60, 2029 max $170.93, 2030 max $209.49, 2040 max $797.07, and 2050 max $1,646.92.
A major floor 19.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 21.7% above — a clean break opens room to run.
A major ceiling 28.9% above — clearing it would confirm fresh momentum.
Key CGON support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGON market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $63.26 | Sell | $62.87 | Sell |
| MA 10 | $65.30 | Sell | $64.45 | Sell |
| MA 20 | $66.69 | Sell | $65.88 | Sell |
| MA 50 | $67.15 | Sell | $65.27 | Sell |
| MA 100 | $60.92 | Sell | $60.56 | Buy |
| MA 200 | $49.33 | Buy | $52.45 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.42 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -147.21 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.90 | Sell |
| ROC (12) | -12.67 | Sell |
| Bollinger %B (20,2) | 0.05 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.08 | Sell |
| Awesome (5,34) | -4.26 | Sell |
| Ultimate (7,14,28) | 26.88 | Buy |
| Momentum (10) | -11.27 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 61.96 | Sell |
| ADX (14) | 15.79 | Neutral |
| ATR (14) | 1.52 | Info |
The market mood is described as BULLISH. The RSI14 is 40, and the 50-day moving average is $67.30 while the 200-day moving average is $48.96. There is nearby support at $62.93 and resistance at $74.00. The 30-day price range spans from $54.56 to $75.66, and the asset’s annualized volatility is 50.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $40.04 | $60.80 | $89.94 | 0% | Neutral | |
| $71.72 | $89.64 | $118.29 | +47% | Bullish | |
| $80.34 | $102.89 | $140.31 | +69% | Bullish | |
| $83.88 | $109.63 | $153.45 | +80% | Bullish | |
| $97.29 | $129.48 | $185.29 | +113% | Bullish | |
| $103.25 | $139.69 | $203.82 | +130% | Bullish | |
| $116.07 | $159.46 | $236.76 | +162% | Bullish | |
| $149.98 | $209.01 | $315.29 | +244% | Bullish | |
| $161.82 | $228.62 | $349.94 | +276% | Bullish | |
| $167.31 | $239.47 | $371.58 | +294% | Bullish | |
| $263.19 | $399.58 | $656.53 | +557% | Bullish | |
| $439.25 | $737.40 | $1,317.76 | +11.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $40.04 | $60.80 | $71.36 | +0.00% |
| June 2026 | $53.41 | $62.61 | $75.03 | +2.97% |
| July 2026 | $54.42 | $64.27 | $77.98 | +2.66% |
| August 2026 | $54.02 | $64.18 | $78.61 | -0.14% |
| September 2026 | $55.17 | $65.87 | $81.29 | +2.62% |
| October 2026 | $58.04 | $69.61 | $86.51 | +5.68% |
| November 2026 | $59.11 | $71.18 | $89.01 | +2.26% |
| December 2026 | $59.17 | $71.52 | $89.94 | +0.47% |
Click any year to see its month-by-month CGON forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
CG Oncology, Inc.'s 2026 outlook centres on $60.80, within a $40.04 to $89.94 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CGON could reach as high as $118.29, with a base case around $89.64 and support toward $71.72 — roughly +47% from $60.80. Buyers look set to stay in control over this stretch.
Expect CGON to range from $80.34 to $140.31 through 2028. The $102.89 average target implies a +69% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The CGON price prediction for 2029 points to an average of $109.63 (low $83.88, high $153.45) — a potential gain of +80% on today's $60.80. Buyers look set to stay in control over this stretch.
In 2030, CGON is projected to trade between $97.29 and $185.29, averaging $129.48 — a potential gain of +113% from today's $60.80. That is up +18% on the projected 2029 average. Momentum favours further upside here.
CG Oncology, Inc.'s 2031 outlook centres on $139.69, within a $103.25 to $203.82 range. That is up +8% on the projected 2030 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CGON could reach as high as $236.76, with a base case around $159.46 and support toward $116.07 — roughly +162% from $60.80. Momentum favours further upside here.
Expect CGON to range from $149.98 to $315.29 through 2033. The $209.01 average target implies a +244% move from current prices. That is up +31% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CGON price prediction for 2034 points to an average of $228.62 (low $161.82, high $349.94) — a potential gain of +276% on today's $60.80. Momentum favours further upside here.
In 2035, CGON is projected to trade between $167.31 and $371.58, averaging $239.47 — a potential gain of +294% from today's $60.80. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
CG Oncology, Inc.'s 2040 outlook centres on $399.58, within a $263.19 to $656.53 range. That is up +67% on the projected 2035 average. That marks a +557% change versus current levels. Momentum favours further upside here.
By 2050, CGON could reach as high as $1,317.76, with a base case around $737.40 and support toward $439.25 — roughly +11.1x from $60.80. Buyers look set to stay in control over this stretch.
Investing $1,000 in CGON today (≈ 16.447368 CGON) could be worth
$12,128.32
+$11,128.32 (+1113%) by 2050 · US Dollar
Based on the average projected CGON price of $737.4 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGONwould be worth at today's price.
$1,000 invested in CGON on May 27, 2025 (≈ 39.184952 CGON) would be worth
$2,382.45
+$1,382.45 (+138.2%) today · 2.38× · US Dollar
Based on a CGON entry price of $25.52 vs. today's $60.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $64.76 | $938.85 | -6.1% |
| 1 month ago | $66.82 | $909.91 | -9.0% |
| 3 months ago | $56.11 | $1,083.59 | +8.4% |
| 6 months ago | $44.84 | $1,355.93 | +35.6% |
| 1 year ago | $25.52 | $2,382.45 | +138.2% |
| All time (2.3y) ago | $37.17 | $1,635.73 | +63.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGON forecast.
Our base-case forecast reaches $120.00 around 2030.
Implied market cap at $120.00: $10.58B
The multi-year forecast shows sustained upside with bullish sentiment through the 2020s and into the 2030s and beyond. By 2030 the average price is $146.36 with a max of $209.49 and an ROI of 127.8; by 2040 the average price rises to $485.13 with a max of $797.07 and an ROI of 655.1; by 2050 the average price is $921.71 with a max of $1,646.92 and an ROI of 1334.6. Earlier years also point to continued growth: 2027 average $97.17, 2028 $112.59, 2029 $122.08, 2031 $159.16, 2032 $185.70, 2033 $245.70, 2034 $267.38, and 2035 $282.20.
These figures are forecasts and carry uncertainty; outcomes depend on clinical results, regulatory decisions, and market dynamics.
Tap a question to reveal the answer.
Avg price in 2030: $146.36; range $109.96-$209.49; ROI 127.8; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages, though 2026 is neutral. Long-term upside is possible but not guaranteed and depends on future outcomes.
Yes. The 2030 max is $209.49; the 2031 max is $232.25; the 2040 max is $797.07; the 2050 max is $1,646.92.
Current price $64.25; market cap $5.67B.
30-day range is $54.56 to $75.66; support at $62.93 and resistance at $74.00; RSI14 is 40; SMA50 is $67.30 and SMA200 is $48.96; annualized volatility 50; sentiment BULLISH.
CG Oncology, Inc. Community Discussion
0Share your CG Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.